These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. Subbiah V; Wolff JE Pediatr Blood Cancer; 2010 Jan; 54(1):180-1. PubMed ID: 19722276 [No Abstract] [Full Text] [Related]
5. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Küsters-Vandevelde HV; Willemsen AE; Groenen PJ; Küsters B; Lammens M; Wesseling P; Djafarihamedani M; Rijntjes J; Delye H; Willemsen MA; van Herpen CM; Blokx WA Acta Neuropathol Commun; 2014 Apr; 2():41. PubMed ID: 24713450 [TBL] [Abstract][Full Text] [Related]
6. Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis. Salgado CM; Basu D; Nikiforova M; Hamilton RL; Gehris R; Jakacki R; Panigrahy A; Yatsenko S; Reyes-Múgica M Melanoma Res; 2015 Oct; 25(5):453-60. PubMed ID: 26266759 [TBL] [Abstract][Full Text] [Related]
7. Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy. Ruan Y; Kovalchuk A; Jayanthan A; Lun X; Nagashima Y; Kovalchuk O; Wright JR; Pinto A; Kirton A; Anderson R; Narendran A Neuro Oncol; 2015 Jun; 17(6):822-31. PubMed ID: 25395461 [TBL] [Abstract][Full Text] [Related]
8. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. Kinsler VA; Thomas AC; Ishida M; Bulstrode NW; Loughlin S; Hing S; Chalker J; McKenzie K; Abu-Amero S; Slater O; Chanudet E; Palmer R; Morrogh D; Stanier P; Healy E; Sebire NJ; Moore GE J Invest Dermatol; 2013 Sep; 133(9):2229-36. PubMed ID: 23392294 [TBL] [Abstract][Full Text] [Related]
9. AN 11-Year-Old Boy with a Leptomeningeal Tumor. Habougit C; Forest F; Boutet C; Douchet C; Stephan JL; Stachowicz ML; Vassal F; Péoc'h M Brain Pathol; 2017 Jul; 27(4):553-554. PubMed ID: 28585389 [No Abstract] [Full Text] [Related]
10. Neurocutaneous melanosis. Di Rocco F; Sabatino G; Koutzoglou M; Battaglia D; Caldarelli M; Tamburrini G Childs Nerv Syst; 2004 Jan; 20(1):23-8. PubMed ID: 14576958 [TBL] [Abstract][Full Text] [Related]
11. Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases. Uguen A; Laurent C; Samaison L; Boisselier B; Talagas M; Costa S; Aziza J; Mokhtari K; Le Maréchal C; Marcorelles P Hum Pathol; 2015 Aug; 46(8):1189-96. PubMed ID: 26037215 [TBL] [Abstract][Full Text] [Related]
12. Neurocutaneous melanosis presenting with hydrocephalus and malignant transformation: case-based update. Sharouf F; Zaben M; Lammie A; Leach P; Bhatti MI Childs Nerv Syst; 2018 Aug; 34(8):1471-1477. PubMed ID: 29948137 [TBL] [Abstract][Full Text] [Related]
13. Neurosurgical management of patients with neurocutaneous melanosis: a systematic review. Rahman RK; Majmundar N; Ghani H; San A; Koirala M; Gajjar AA; Pappert A; Mazzola CA Neurosurg Focus; 2022 May; 52(5):E8. PubMed ID: 35535823 [TBL] [Abstract][Full Text] [Related]
14. Neurocutaneous melanocytosis (melanosis). Ruggieri M; Polizzi A; Catanzaro S; Bianco ML; Praticò AD; Di Rocco C Childs Nerv Syst; 2020 Oct; 36(10):2571-2596. PubMed ID: 33048248 [TBL] [Abstract][Full Text] [Related]
15. Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. Ramaswamy V; Delaney H; Haque S; Marghoob A; Khakoo Y Dev Med Child Neurol; 2012 Jun; 54(6):563-8. PubMed ID: 22469364 [TBL] [Abstract][Full Text] [Related]
16. Leptomeningeal melanomatosis associated with neurocutaneous melanosis: an autopsy case report. Matsumura M; Okudela K; Tateishi Y; Umeda S; Mitsui H; Suzuki T; Nakayama T; Inayama Y; Ohashi K Pathol Int; 2015 Feb; 65(2):100-5. PubMed ID: 25521302 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis. Shih F; Yip S; McDonald PJ; Chudley AE; Del Bigio MR Acta Neuropathol Commun; 2014 Oct; 2():140. PubMed ID: 25330907 [TBL] [Abstract][Full Text] [Related]
18. Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis. Takahashi H; Natsumeda M; Hara N; Koyama A; Shimizu H; Miyashita A; Satake D; Mouri Y; Tsukano J; Kawabe K; Tsukamoto Y; Okada M; Ogura R; Yuki A; Umezu H; Kakita A; Ikeuchi T; Oishi M Acta Neuropathol Commun; 2024 Jan; 12(1):14. PubMed ID: 38254245 [TBL] [Abstract][Full Text] [Related]
19. Neurocutaneous melanomatosis with a rapidly deteriorating course. Chu WC; Lee V; Chan YL; Shing MM; Chik KW; Li CK; Ma KC AJNR Am J Neuroradiol; 2003 Feb; 24(2):287-90. PubMed ID: 12591651 [TBL] [Abstract][Full Text] [Related]
20. A newborn with neurocutaneous melanocytosis and Dandy-Walker malformation. De Cock J; Snauwaert J; Van Rompaey W; Morren MA; Demaerel P Pediatr Neurol; 2014 Mar; 50(3):276-8. PubMed ID: 24321541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]